AB Science
Researches and develops protein kinase inhibitors for human and veterinary medicine.
AB | PA
Overview
Corporate Details
- ISIN(s):
- FR0010557264 (+1 more)
- LEI:
- 969500U43TVR8CCVBJ97
- Country:
- France
- Address:
- 3 AVENUE GEORGE V, 75008 PARIS
- Website:
- https://www.ab-science.com
- Sector:
- Manufacturing
Description
AB Science is a clinical-stage pharmaceutical company that researches, develops, and markets protein kinase inhibitors for human and veterinary medicine. The company focuses on developing innovative drugs for diseases with high unmet medical needs. Its pipeline is centered on two main compounds: masitinib and AB8939. Masitinib, a highly selective tyrosine kinase inhibitor, is under investigation for treating neurodegenerative disorders such as Amyotrophic Lateral Sclerosis (ALS) and Alzheimer's disease, as well as inflammatory diseases like mastocytosis. AB8939 is a microtubule destabilizer being developed for oncology, specifically for Acute Myeloid Leukemia (AML). The company also commercializes masitinib in veterinary medicine under the brand name Masivet®.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Type / Size | Actions | |
|---|---|---|---|---|---|
| 2025-12-22 17:57 |
Le brevet pour le masitinib dans le traitement de la drépanocyose a été officie…
|
French | PDF • 219.8 KB | ||
| 2025-12-22 17:57 |
AB Science patent for masitinib in the treatment of sickle cell disease formall…
|
English | PDF • 225.2 KB | ||
| 2025-12-18 19:17 |
AB Science announces the initiation of coverage of its stock by Maxim Group wit…
|
English | PDF • 200.2 KB | ||
| 2025-12-18 19:17 |
AB Science annonce l’initiation de la couverture de son titre par Maxim Group a…
|
French | PDF • 202.2 KB | ||
| 2025-12-15 18:39 |
AB Science annonce une nouvelle publication sur biorxiv identifiant AB8939 comm…
|
French | PDF • 291.3 KB | ||
| 2025-12-15 18:39 |
AB Science announces a new publication on biorxiv that identifies AB8939 as a p…
|
English | PDF • 290.4 KB | ||
| 2025-12-11 18:29 |
AB Science announces new publication on Medrxiv highlighting clinical benefit w…
|
English | PDF • 255.0 KB | ||
| 2025-12-11 18:29 |
AB Science annonce une nouvelle publication sur Medrxiv mettant en évidence le …
|
French | PDF • 252.5 KB | ||
| 2025-10-17 08:00 |
AB Science annonce le succès d'un placement privé de 2,8 millions d'euros
|
French | PDF • 363.8 KB | ||
| 2025-10-17 08:00 |
AB Science announces the successful completion of a EUR 2.8 million private pla…
|
English | PDF • 336.2 KB | ||
| 2025-10-16 20:57 |
AB Science présente les premières données de phase 1 de la combinaison d’AB8939…
|
French | PDF • 307.8 KB | ||
| 2025-10-16 20:57 |
AB Science provides intitial Phase 1 data for the combination of AB8939 with ve…
|
English | PDF • 306.4 KB | ||
| 2025-10-14 08:36 |
AB Science tiendra une conférence virtuelle le jeudi 16 octobre 2025, de 14 h à…
|
French | PDF • 266.0 KB | ||
| 2025-10-14 08:36 |
AB Science will hold a virtual conference on Thursday, October 16, 2025 from 2…
|
English | PDF • 266.2 KB | ||
| 2025-10-10 18:10 |
AB Science today reports its revenues for the first half of 2025 and provides a…
|
English | PDF • 279.4 KB |
Automate Your Workflow. Get a real-time feed of all AB Science filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for AB Science
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for AB Science via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
